BeOne Medicines Reaches US Accord on Drug Access, Domestic Manufacturing
MT Newswires Live
Yesterday
BeOne Medicines (ONC) voluntarily agreed with the US government to expand patient access to its cancer medicines and increase US manufacturing operations, the company said Monday.
The company said it will join a federal pricing framework that requires future products approved by the Food and Drug Administration to be priced in line with other developed markets.
Switzerland-based BeOne also reached an agreement with the US that rewards its decision to manufacture more of its medicines domestically by exempting it from certain national-security-based import tariffs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.